Lithotripsy

The Worldwide Kidney Stone Retrieval Devices Industry is Expected to Reach $3.6 Billion by 2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, September 23, 2022

Kidney stone retrieval devices are used in minimally invasive or non-invasive treatment options for the removal of kidney stones.

Key Points: 
  • Kidney stone retrieval devices are used in minimally invasive or non-invasive treatment options for the removal of kidney stones.
  • Considerably smaller ureter scopes, quartz fibers, and lithotripter probes have made the extraction of kidney stones from previously unreachable locations far safer than traditional surgical options.
  • For instance, the Dretler stone cone is one innovation that inhibits stone migration during the treatment.
  • The demand for kidney stone retrieval devices was uneven, with installation delays and a decline in manufacturing during the pandemic.

AVS Announces Multi-Site Enrollment of First Patients in POWER PAD I Clinical Trial and Appointment of William H. Kucheman to Board of Directors

Retrieved on: 
Thursday, September 15, 2022

AVS is only the second company to conduct a first-in-human study in the rapidly growing intravascular lithotripsy space.

Key Points: 
  • AVS is only the second company to conduct a first-in-human study in the rapidly growing intravascular lithotripsy space.
  • AVS is the first company to develop pulsatile intravascular lithotripsy, a therapy that is delivered through a balloon-based platform called PULSE.
  • We are excited by this first-in-human trial milestone we have achieved, added Mark Toland, President and Chief Executive Officer of AVS.
  • Kucheman added, I am delighted to join the AVS board and look forward to helping patients with limited treatment options.

ADVANCED MEDTECH ACQUIRES WIKKON, STRENGTHENING ITS MARKET LEADING POSITION IN UROLOGY MEDICAL DEVICES

Retrieved on: 
Tuesday, September 13, 2022

Integrated urology leaderAdvanced MedTech Holdings (AMTH or the Group) announced the acquisition of a majority interest in WIKKON, the Chinese market leader in urology and shock wave therapy devices.

Key Points: 
  • Integrated urology leaderAdvanced MedTech Holdings (AMTH or the Group) announced the acquisition of a majority interest in WIKKON, the Chinese market leader in urology and shock wave therapy devices.
  • Abel Ang, Group Chief Executive of Advanced MedTech, said: We are now uniquely placed to aggressively grow in Chinas sizeable market, which is best served by domestically produced devices.
  • Advanced MedTech Holdings is a global medical technology leader with a core focus in urology devices and contract manufacturing services.
  • Advanced MedTech Holdings makes strategic investments in disruptive medical technology companies, strengthening its portfolio of healthcare solutions for customers around the world.

First-on-Podium Data from 21 Vascular Interventional Clinical Trials to Be Presented at The VEINS and VIVA 2022

Retrieved on: 
Thursday, September 1, 2022

VIVA (Vascular InterVentional Advances) is a vascular education symposium that emphasizes innovation and multidisciplinary learning.

Key Points: 
  • VIVA (Vascular InterVentional Advances) is a vascular education symposium that emphasizes innovation and multidisciplinary learning.
  • The VEINS (Venous Endovascular INterventional Strategies) is a comprehensive education symposium focused on the diagnosis, intervention, and management of venous disorders.
  • VIVA and The VEINS bring together a global, multispecialty faculty to present a variety of talks and live case presentations from clinical centers around the world.
  • Attendees for both events include an audience of interventional cardiologists, interventional radiologists, vascular surgeons, and endovascular medicine specialists.

$1.87 Billion Lithotripsy Devices Market Insights, Competitive Landscape and Market Forecasts, 2027 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 10, 2022

The "Lithotripsy Devices Market Insights, Competitive Landscape and Market Forecast - 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Lithotripsy Devices Market Insights, Competitive Landscape and Market Forecast - 2027" report has been added to ResearchAndMarkets.com's offering.
  • Global Lithotripsy Devices Market was valued at USD 1.44 billion in 2021, growing at a CAGR of 4.35% during the forecast period from 2022 to 2027, to reach USD 1.87 billion by 2027.
  • Such technological advancement in the field of Lithotripsy Devices is likely to boost the Global Lithotripsy Devices Market during the forecast period.
  • Which are the regions and countries where companies should have concentrated on opportunities for Lithotripsy Devices market growth in the coming future?

Insights on the Energy-Based Therapeutics Global Market to 2027 - by Technology Type, Clinical Application, End-user and Region - ResearchAndMarkets.com

Retrieved on: 
Monday, June 20, 2022

These therapeutics are divided on the basis of clinical applications into general, ophthalmic and aesthetic surgeries.

Key Points: 
  • These therapeutics are divided on the basis of clinical applications into general, ophthalmic and aesthetic surgeries.
  • Key Questions Answered in This Report:
    How has the global energy-based therapeutics market performed so far and how will it perform in the coming years?
  • What is the structure of the global energy-based therapeutics industry and who are the key players?
  • What is the degree of competition in the global energy-based therapeutics industry?

US Surgical Procedures Market Analysis Report 2022-2027: Focus on Gastrointestinal, Cardiovascular, Dental, Cosmetic, Urologic, Ophthalmic, Orthopedic, ENT, Gynecologic Surgical Procedures - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 16, 2022

The "US Surgical Procedures Market by Type (Gastrointestinal, Cardiovascular, Dental, Cosmetic, Urologic, Ophthalmic, Orthopedic, ENT, Gynecologic Surgical Procedures), Channel (Physician Offices, Hospitals, (Inpatient, Outpatient), ASC) - Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Surgical Procedures Market by Type (Gastrointestinal, Cardiovascular, Dental, Cosmetic, Urologic, Ophthalmic, Orthopedic, ENT, Gynecologic Surgical Procedures), Channel (Physician Offices, Hospitals, (Inpatient, Outpatient), ASC) - Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.
  • Advances in surgical, anesthetic, and intensive care techniques have led a larger proportion of expanding elderly population to undergo surgical procedures, which will drive the growth of the US surgical procedures market.
  • Based on type, the US surgical procedures market is segmented into gastrointestinal surgical procedures, cardiovascular surgical procedures, dental surgical procedures, cosmetic surgical procedures, urologic surgical procedures, ophthalmic surgical procedures, orthopedic surgical procedures, ENT surgical procedures, obstetric/gynecologic surgical procedures, and other surgical procedures.
  • In 2021, the dental surgical procedures segment accounted for the largest share of this market.

EDAP Reports First Quarter 2022 Results

Retrieved on: 
Tuesday, May 17, 2022

Total revenue in the HIFU business for the first quarter 2022 was EUR 3.8 million (USD 4.3 million), as compared to EUR 1.8 million (USD 2.2 million) for the first quarter of 2021.

Key Points: 
  • Total revenue in the HIFU business for the first quarter 2022 was EUR 3.8 million (USD 4.3 million), as compared to EUR 1.8 million (USD 2.2 million) for the first quarter of 2021.
  • Total revenue in the LITHO business for the first quarter 2022 was EUR 2.2 million (USD 2.5 million), as compared to EUR 2.9 million (USD 3.5 million) for the first quarter of 2021.
  • Total revenue in the Distribution business for the first quarter 2022 was EUR 7.0 million (USD 7.8 million), as compared to EUR 5.6 million (USD 6.7 million) for the first quarter of 2021.
  • Operating loss for the first quarter of 2022 was EUR 0.1 million (USD 0.1 million), compared to an operating profit of EUR 0.2 million (USD 0.3 million) in the first quarter of 2021.

SKIA Develops SKIA_Breast, AR Navigation on Patient Body for Doctors

Retrieved on: 
Monday, May 9, 2022

Without having to visualize a two-dimensional image on the monitor as three-dimensional, the surgeon can concentrate more on the operation.

Key Points: 
  • Without having to visualize a two-dimensional image on the monitor as three-dimensional, the surgeon can concentrate more on the operation.
  • SKIA_Breast can see through the human body, so it helps to reduce any deviation of skill level according to surgical experience.
  • SKIA Co., Ltd. is a medical extended reality software development startup which was established on September 1, 2018.
  • In the future, we will develop a solution that can be applied to other organs such as liver and pancreas.

Conavi Medical’s Novasight Hybrid System Now In Use at Sunnybrook Health Sciences Centre

Retrieved on: 
Thursday, April 28, 2022

Conavi Medical Inc. ( www.conavi.com ), a leader of hybrid imaging guidance for common minimally invasive heart procedures, and Sunnybrook Health Sciences Centre, today announced that the Novasight Hybrid System is now being used for clinical procedures by interventional cardiologists as part of the Schulich Heart Program.

Key Points: 
  • Conavi Medical Inc. ( www.conavi.com ), a leader of hybrid imaging guidance for common minimally invasive heart procedures, and Sunnybrook Health Sciences Centre, today announced that the Novasight Hybrid System is now being used for clinical procedures by interventional cardiologists as part of the Schulich Heart Program.
  • The hybrid intravascular ultrasound (IVUS) and optical coherence tomography (OCT) imaging platform, now called Novasight Hybrid System, was initially invented at Sunnybrook Research Institute (SRI) by Dr. Brian Courtney, a scientist and interventional cardiologist.
  • In fact, its a key part of our strategic plan, said Andy Smith, President and CEO of Sunnybrook Health Sciences Centre.
  • Novasight Hybrid System has 510(k) clearance from the U.S. Food and Drug Administration, and regulatory approval for clinical use from Health Canada, and the Ministry of Health, Labor and Welfare (MHLW) in Japan.